Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI filing briefs · archive

8-K filings in May 2025, explained

1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

1 of 1,080 briefs matches

newest first · times in ET
ANIPANI PHARMACEUTICALS INC May 20, 8:05 AM ET

ANI Pharmaceuticals raises 2025 revenue guidance to $768-793 million in investor deck

Positive guidance Written later 2.027.01

ANI Pharmaceuticals filed an investor presentation for the H.C. Wainwright BioConnect conference on May 20, 2025, where CEO Nikhil Lalwani is scheduled to present. The deck restates the revised full-year 2025 guidance issued May 9, 2025, which raised net revenue to $768-793 million from $756-776 million and adjusted EBITDA to $195-205 million from $190-200 million, and describes this as the second guidance raise this year.

  • Full-year 2025 net revenue guidance is $768-793 million, up from $756-776 million; the deck calls this the second guidance raise in 2025.
  • Adjusted non-GAAP diluted EPS guidance is $6.27-6.62, up from $6.12-6.49.
  • Q1 2025 total revenue was $197 million, up 43% year over year; Q1 adjusted non-GAAP EBITDA was $51 million, up 35%.
  • CEO Nikhil Lalwani will present on May 20, 2025 at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.